Predictive diagnostics for hormone receptor positive breast

Hormone receptor positive breast cancer is most common type of breast cancer with an impressive overall survival due to targeted endocrine therapy. However, the recurrence is common due to endocrine therapy resistance. There are no standard guidelines for endocrine therapy period (5 years vs 10 years). Oncodrex’s Predictive Diagnostics remove the fear of “WHAT IF COMES BACK” by predicting the likelihood of HR+ breast cancer recurrence. The IHC based predictive test could easily be adopted by including in the primary tumor receptor status panel